GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: May 9, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | May 9, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-repurchase
Related Tickers: GSK
TL;DR
GSK is buying back its own stock via Citigroup.
AI Summary
GSK plc announced on May 9, 2025, that it purchased a number of its own ordinary shares through its corporate stockbroker, Citigroup Global Markets Limited. The filing does not specify the exact number of shares or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of share repurchases and does not indicate any new or significant risks.
Key Players & Entities
- GSK plc (company) — The company making the share repurchase.
- Citigroup Global Markets Limited (company) — The corporate stockbroker acting on behalf of GSK plc for the share repurchase.
- May 9, 2025 (date) — The date of the announcement and purchase.
FAQ
What is the total number of GSK ordinary shares purchased?
The filing states that a 'number' of ordinary shares were purchased but does not specify the exact quantity.
What is the total dollar amount spent on the share repurchases?
The filing does not disclose the total dollar amount spent on the share repurchases.
Through which entity did GSK conduct these share repurchases?
GSK acted through its corporate stockbroker, Citigroup Global Markets Limited.
What is the par value of GSK's ordinary shares?
The ordinary shares have a par value of 31 1/4 pence each.
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, specifically reporting a transaction in own shares.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 9, 2025 regarding GSK plc (GLAXF).